Remove Biopharma Remove Leads Remove Side effects
article thumbnail

CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug

MedCity News

Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder.

article thumbnail

Leading speciality pharmacies in pharma

Pharmaceutical Technology

Speciality pharmacies play a crucial role in medication dosing, disease and side effects management, and patient care. The post Leading speciality pharmacies in pharma appeared first on Pharmaceutical Technology. Value-based delivery models encourage providers to target costs, quality, and health outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Merck’s $1.3B Imago Buyout Brings Blood Cancer Drug to Rival BMS, Incyte & GSK

MedCity News

Merck is acquiring Imago BioSciences, a clinical-stage biotech whose lead drug is in development for myelofibrosis and other blood cancers. The deal gives the pharmaceutical giant a small molecule that could provide an alternative to a class of drugs that introduce dangerous side effects.

article thumbnail

Liver injuries prompt clinical hold on Sanofi BTK drug

pharmaphorum

billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. All the BTK inhibitors are designed to be able to cross the blood brain barrier and enter the central nervous system, dampening down the autoimmune response that leads to neuronal damage in MS.

article thumbnail

Practical advice for Early Scientific Advice (ESA) in HTA submissions

pharmaphorum

In recent years, the biopharma market has become progressively complex. Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors.

article thumbnail

FOCUS ON – Crowdsource/Adherence and Compliance

PM360

DANNY SIGURDSON CEO and Founder Courier Health To effectively engage patients and prescribers to improve overall adherence to prescribed medication regimens, biopharma companies first need the visibility and full context of where a patient stands in their treatment journey. Patients’ challenges are diverse.

article thumbnail

Roche takes another punt on IL-2 in cancer with Good takeover

pharmaphorum

Good’s lead drug is due to start clinical testing next year. Foremost among those was Bristol-Myers Squibb and Nektar’s bempegaldesleukin, a pegylated form of recombinant IL-2 that aimed to extend the half-life of the cytokine in the body, extending the time between doses, and simultaneously reducing side effects.